Literature DB >> 26975867

Financial Burden of Cancer Clinical Trial Participation and the Impact of a Cancer Care Equity Program.

Ryan D Nipp1, Hang Lee2, Elizabeth Powell2, Nicole E Birrer2, Emily Poles2, Daniel Finkelstein2, Karen Winkfield2, Sanja Percac-Lima2, Bruce Chabner2, Beverly Moy2.   

Abstract

INTRODUCTION: Cancer clinical trial (CT) participation rates are low and financial barriers likely play a role. We implemented a cancer care equity program (CCEP) to address financial burden associated with trial participation. We sought to examine the impact of the CCEP on CT enrollment and to assess barriers to participation.
METHODS: We used an interrupted time series design to determine trends in CT enrollment before and after CCEP implementation. Linear regression models compared trial enrollment before and after the CCEP. We also compared patient characteristics before and after the CCEP and between CCEP and non-CCEP participants. We surveyed CCEP and non-CCEP participants to compare pre-enrollment financial barriers.
RESULTS: After accounting for increased trial availability and the trends in accrual for prior years, we found that enrollment increased after CCEP implementation (18.97 participants per month greater than expected; p < .001). A greater proportion of CCEP participants were younger, female, in phase I trials, lived farther away, had lower incomes, and had metastatic disease. Of 87 participants who completed the financial barriers survey, 49 CCEP and 38 matched, non-CCEP participants responded (63% response rate). CCEP participants were more likely to report concerns regarding finances (56% vs. 11%), medical costs (47% vs. 14%), travel (69% vs. 11%), lodging (60% vs. 9%), and insurance coverage (43% vs. 14%) related to trial participation (all p < .01).
CONCLUSION: CT participation increased following implementation of the CCEP and the program enrolled patients experiencing greater financial burden. These findings highlight the need to address the financial burden associated with CT participation. IMPLICATIONS FOR PRACTICE: Financial barriers likely discourage patients from participating in clinical trials. Implementation of a cancer care equity program (CCEP) seeking to reduce financial barriers by assisting with travel and lodging costs was associated with increased trial accrual. The CCEP provided assistance to patients particularly in need, including those living farther away, those with lower incomes, and those reporting financial barriers related to trial participation. These findings suggest that financial concerns represent a major barrier to patient participation in clinical trials and underscore the importance of efforts to address these concerns. ©AlphaMed Press.

Entities:  

Keywords:  Clinical trial; Cost of illness; Financial support; Health care costs; Quality of life

Mesh:

Year:  2016        PMID: 26975867      PMCID: PMC4828126          DOI: 10.1634/theoncologist.2015-0481

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  49 in total

1.  Responsibility for costs associated with clinical trials.

Authors:  Paul J Martin; Nancy Davenport-Ennis; Nicholas J Petrelli; F Marc Stewart; Frederick R Appelbaum; Al Benson
Journal:  J Clin Oncol       Date:  2014-09-15       Impact factor: 44.544

2.  Barriers to the participation of African-American patients with cancer in clinical trials: a pilot study.

Authors:  Anjali S Advani; Benjamin Atkeson; Carrie L Brown; Bercedis L Peterson; Laura Fish; Jeffrey L Johnson; Jon P Gockerman; Marc Gautier
Journal:  Cancer       Date:  2003-03-15       Impact factor: 6.860

3.  How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials.

Authors:  Warren B Sateren; Edward L Trimble; Jeffrey Abrams; Otis Brawley; Nancy Breen; Leslie Ford; Mary McCabe; Richard Kaplan; Malcolm Smith; Richard Ungerleider; Michaele C Christian
Journal:  J Clin Oncol       Date:  2002-04-15       Impact factor: 44.544

4.  Application of best practice approaches for designing decision support tools: the preparatory education about clinical trials (PRE-ACT) study.

Authors:  Linda Fleisher; Dominique G Ruggieri; Suzanne M Miller; Sharon Manne; Terrance Albrecht; Joanne Buzaglo; Michael A Collins; Michael Katz; Tyler G Kinzy; Tasnuva Liu; Cheri Manning; Ellen Specker Charap; Jennifer Millard; Dawn M Miller; David Poole; Stephanie Raivitch; Nancy Roach; Eric A Ross; Neal J Meropol
Journal:  Patient Educ Couns       Date:  2014-04-21

5.  The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience.

Authors:  S Yousuf Zafar; Jeffrey M Peppercorn; Deborah Schrag; Donald H Taylor; Amy M Goetzinger; Xiaoyin Zhong; Amy P Abernethy
Journal:  Oncologist       Date:  2013-02-26

6.  The impact of serious illness on patients' families. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatment.

Authors:  K E Covinsky; L Goldman; E F Cook; R Oye; N Desbiens; D Reding; W Fulkerson; A F Connors; J Lynn; R S Phillips
Journal:  JAMA       Date:  1994-12-21       Impact factor: 56.272

7.  Overcoming barriers to cancer clinical trial accrual: impact of a mass media campaign.

Authors:  Ari Umutyan; Christine Chiechi; Laurel A Beckett; Debora A Paterniti; Corinne Turrell; David R Gandara; Sharon W Davis; Ted Wun; Moon S Chen; Primo N Lara
Journal:  Cancer       Date:  2008-01-01       Impact factor: 6.860

8.  Participation in cancer clinical trials: race-, sex-, and age-based disparities.

Authors:  Vivek H Murthy; Harlan M Krumholz; Cary P Gross
Journal:  JAMA       Date:  2004-06-09       Impact factor: 56.272

9.  Incremental treatment costs in national cancer institute-sponsored clinical trials.

Authors:  Dana P Goldman; Sandra H Berry; Mary S McCabe; Meredith L Kilgore; Arnold L Potosky; Michael L Schoenbaum; Matthias Schonlau; Jane C Weeks; Richard Kaplan; Jose J Escarce
Journal:  JAMA       Date:  2003-06-11       Impact factor: 56.272

10.  Informing breast cancer patients about clinical trials: a randomized clinical trial of an educational booklet.

Authors:  P M Ellis; P N Butow; M H N Tattersall
Journal:  Ann Oncol       Date:  2002-09       Impact factor: 32.976

View more
  22 in total

1.  Science in the Heartland: Exploring determinants of offering cancer clinical trials in rural-serving community urology practices.

Authors:  Shellie D Ellis; Mugur Geana; Christine B Mackay; Deborah J Moon; Jessie Gills; Andrew Zganjar; Gayle Brekke; J Brantley Thrasher; Tomas L Griebling
Journal:  Urol Oncol       Date:  2019-03-29       Impact factor: 3.498

2.  At What Cost to Clinical Trial Enrollment? A Retrospective Study of Patient Travel Burden in Cancer Clinical Trials.

Authors:  Hala T Borno; Li Zhang; Adam Siegel; Emily Chang; Charles J Ryan
Journal:  Oncologist       Date:  2018-04-26

3.  Health policy: Overcoming cost barriers to clinical trial participation.

Authors:  Neal J Meropol
Journal:  Nat Rev Clin Oncol       Date:  2016-05-20       Impact factor: 66.675

4.  Assessment of adherence and relative dose intensity with oral chemotherapy in oncology clinical trials at an academic medical center.

Authors:  Jeff A Engle; Anne M Traynor; Toby C Campbell; Kari B Wisinski; Noelle LoConte; Glenn Liu; George Wilding; Jill M Kolesar
Journal:  J Oncol Pharm Pract       Date:  2017-04-29       Impact factor: 1.809

5.  Cancer clinical trials in the Philippines.

Authors:  Michelle Ann B Eala; Patricia Anne S Basilio; Edward Christopher Dee; Reno Eufemon P Cereno; Christian Daniel Ang; Nikko J Magsanoc; Frederic Ivan L Ting; Dennis L Sacdalan
Journal:  Cancer Causes Control       Date:  2022-07-20       Impact factor: 2.532

6.  Patient Experience in Clinical Trials: Quality of Life, Financial Burden, and Perception of Care in Patients With Multiple Myeloma or Lymphoma Enrolled on Clinical Trials Compared With Standard Care.

Authors:  Surbhi Sidana; Cristine Allmer; Melissa C Larson; Amylou Dueck; Kathleen Yost; Rahma Warsame; Gita Thanarajasingam; James R Cerhan; Jonas Paludo; S Vincent Rajkumar; Thomas M Habermann; Grzegorz S Nowakowski; Yi Lin; Morie A Gertz; Thomas Witzig; Angela Dispenzieri; Wilson I Gonsalves; Stephen M Ansell; Carrie A Thompson; Shaji K Kumar
Journal:  JCO Oncol Pract       Date:  2022-05-17

Review 7.  Practices of patient engagement in drug development: a systematic scoping review.

Authors:  Olga Zvonareva; Constanța Craveț; Dawn P Richards
Journal:  Res Involv Engagem       Date:  2022-06-29

8.  Developing a Virtual Equity Hub: Adapting the Tumor Board Model for Equity in Cancer Care.

Authors:  Kelly E Irwin; Naomi Ko; Elizabeth P Walsh; Veronica Decker; Isabel Arrillaga-Romany; Scott R Plotkin; Jeffrey Franas; Emily Gorton; Beverly Moy
Journal:  Oncologist       Date:  2022-07-05       Impact factor: 5.837

9.  Advancing Inclusive Research: Establishing Collaborative Strategies to Improve Diversity in Clinical Trials.

Authors:  Owen Garrick; Ruben Mesa; Andrea Ferris; Edward S Kim; Edith Mitchell; Otis W Brawley; John Carpten; Keith D Carter; Joseph Coney; Robert Winn; Stephanie Monroe; Fabian Sandoval; Edith Perez; Mitzi Williams; Evan Grove; Quita Highsmith; Nicole Richie; Susan M Begelman; Asha S Collins; Jamie Freedman; Melissa S Gonzales; Gerren Wilson
Journal:  Ethn Dis       Date:  2022-01-20       Impact factor: 2.006

10.  Cancer Disparities and Health Equity: A Policy Statement From the American Society of Clinical Oncology.

Authors:  Manali I Patel; Ana Maria Lopez; William Blackstock; Katherine Reeder-Hayes; E Allyn Moushey; Jonathan Phillips; William Tap
Journal:  J Clin Oncol       Date:  2020-08-12       Impact factor: 50.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.